Skip to main
  1. Stocks
  2. Evolent Health
  3. Forecast
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 27%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health is supported by accelerating Performance Suite execution, with 3Q26 revenue of $725.4mm up 51.3% Y/Y and adjusted EBITDA of $34.3mm exceeding expectations, while favorable runout on 2026 launches like Highmark and Aetna suggests reserves are proving conservative. Its outlook is strengthened by contract wins and expansions, including a 4-year Surgical Management renewal, a ~1mm life oncology expansion, and a national payer relationship now spanning 50 states, all of which reinforce the company’s value-based care platform. Fundamentally, the shift toward margin and cash generation is encouraging, with FY26 EBITDA guidance lifted to a $130mm-$135mm range, FY27 adjusted EBITDA reiterated at $150mm+, free cash flow of $19.2mm in 3Q, and up to $50mm of YE debt reduction targeted.

Bears say

Evolent Health is facing a negative setup because its HCIT exposure depends on government-supported spending and value-based care adoption that could slow, while hospital budget pressure, customer losses from consolidation, and greater price competition may restrain demand. The company also flagged slower client signings, existing clients shifting to other vendors, and a roughly 7% membership headwind in Technology & Services, which translates into an approximately 11-12% revenue decline there, including Medicaid and pricing pressure. Although 2026/2027 revenue estimates were raised to $2.63/$3.28 billion and adjusted EBITDA to $131/$150 million, cash from adjustments will not arrive until next year, and management indicated that some potential contracts are not included in the roughly 25% growth framework, leaving EBITDA upside uncertain.

Evolent Health (EVH) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 27% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Evolent Health (EVH) Analyst Forecast & Price Prediction

Get the latest Evolent Health (EVH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Evolent Health (EVH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 11 analysts, Evolent Health (EVH) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Evolent Health (EVH) Analyst Forecast & Price Prediction

Get the latest Evolent Health (EVH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Evolent Health (EVH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover EVH stock data and trends